Rand Paul Introduces Federal Bill to Strip Vaccine Manufacturers of Nationwide Liability Immunity

U.S. Senator Rand Paul (R-KY) has introduced landmark federal legislation aimed at ending the longstanding liability immunity enjoyed by vaccine manufacturers, a move that could expose the industry to civil lawsuits for the first time in decades.

The bill, designated S.3853 and formally titled “A bill to amend the Public Health Service Act to end the liability shield for vaccine manufacturers, and for other purposes,” was introduced on February 11, 2026. It was promptly referred to the Senate Committee on Health, Education, Labor, and Pensions (HELP) for consideration.

If enacted, S.3853 would amend the Public Health Service Act to strip away the legal protections that have shielded vaccine manufacturers from product-liability lawsuits since 1986. These protections have insulated companies from accountability in civil courts despite reported injuries linked to their products.

Supporting the push for reform, CDC data indicate millions of injury reports have been submitted following vaccination. However, an analysis by HHS and Harvard Pilgrim concluded that the agency’s vaccine tracking system captures fewer than 1% of adverse events, raising questions about the true scale of vaccine-related injuries.

Senator Paul’s initiative arrives amid ongoing debates over vaccine safety and manufacturer accountability. The 1986 liability shield was established under the National Childhood Vaccine Injury Act, which created a no-fault compensation program but barred most direct lawsuits against manufacturers.

By targeting this immunity, the legislation seeks to restore standard product liability principles to the vaccine industry, potentially incentivizing greater safety measures and providing injured individuals with direct recourse through the courts.

As the bill advances to the HELP Committee, its fate will depend on bipartisan support and broader Senate dynamics. Proponents argue it addresses a critical gap in oversight, while the pharmaceutical sector has long defended the protections as essential for vaccine development and supply.